Abstract:The Alzheimer's Prevention Initiative (API) was established to conduct prevention trials, clarify biomarker utilities, and share data and sample. We present the trial design and baseline clinical and cognitive data from the API Autosomal Dominant AD (ADAD) Colombia Trial in Presenilin 1 (PSEN1) E280A mutation carriers and non-carriers. This is a placebo-controlled prevention trial of the investigational amyloid-β (Aβ) antibody therapy crenezumab in 252 cognitively unimpaired 30-60-year-old kindred members; mutation carriers were randomized to crenezumab or placebo, non-carriers receive placebo only. We will compare rates of change on drug vs placebo in clinical and biomarker outcomes, addressing whether treatment shows a clinical-biomarker pattern indicative of slowed illness progression. The primary outcome is change in the API ADAD Composite Cognitive Test Score from baseline to week 260. Secondary outcomes include time to progression to mild cognitive impairment/ dementia; changes in dementia severity, memory, and overall neurocognitive functioning; and changes in selected biomarkers. Safety and tolerability are assessed. We developed a baseline data-sharing plan to protect participant identity and trial integrity. Baseline data from multiple sources were shared (July 2018) with firewalled sponsor teams who determined what data could be analyzed and presented. The data presented are from 242 of the 252 enrolled. Statistical tests were not adjusted for multiplicity. Baseline clinical and cognitive data will be presented according to mutation carriage status, including age, sex, years of education, APOE4 carriage, subjective cognitive concern, and scores for the API ADAD Composite Cognitive Test, CDR, FAST, NPI, MMSE, CERAD word list recall, RBANS, and FCSRT. Compared to mutation non-carriers in the trial, mutation carriers were younger (mean 37 vs 42 years), had similar educational attainment (mean 8.8 vs 8.5 years), showed generally lower cognitive performance, with greater variance, especially on measures of memory (e.g., mean RBANS delayed memory 77.4 vs 87.3, respectively); no difference in subjective concerns regarding cognition; small differences in FAST and CDR, with greater variance; and no differences in NPI scores. The API ADAD Colombia Trial baseline data available provide insights into age-associated changes in clinical and cognitive characteristics. Investigators can apply for analysis of baseline data at APIdata@bannerhealth.com.

TRIAL DESIGN, DATA SHARING RISK MITIGATION, AND BASELINE CLINICAL AND COGNITIVE DATA FROM THE API AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE COLOMBIA TRIAL